In this multicentre , randomised , double-blind , placebo-controlled , phase 3 trial ( DECISION ) , we investigated sorafenib ( 400 mg orally twice daily ) in patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within the past 14 months .